Ravulizumab for Paroxysmal Nocturnal Hemoglobinuria

"Ravulizumab has been shown to be safe in multiple clinical trials, so it received a score of 3."

"Currently, there are 25 ongoing Ravulizumab studies in 45 countries and 240 cities. The first clinical trial for the drug was conducted by Alexion Pharmaceuticals in 2016 with 270 participants. As of now, 47 trials have been completed and Phase 3 approval has been granted."

"The primary outcome of this study, which will be measured over a Day 29 through Day 183 time frame is to Percentage Of Participants Who Achieved Transfusion Avoidance (TA). Secondary outcomes include Percentage Of Participants With Stabilized Hemoglobin Levels which is defined as Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline in the absence of transfusion through Day 183., Percentage Of Participants With Breakthrough Hemolysis (BTH) which is defined as Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hem"

"There are 4 primary enrolment centres for this study, situated in Los Angeles, Toronto, and Fort Worth. There are also other locations that participating patients can choose from to minimize travel requirements."

"This trial is not actively searching for patients at this time. The study was first posted on December 20th, 2016 and was most recently edited on July 14th, 2022. If you are seeking other studies, there are currently 33 clinical trials actively recruiting patients with hemoglobinuria paroxysmal and 25 trials for Ravulizumab actively enrolling patients."

"Ravulizumab can be used as a treatment for patients who are complement inhibitor naive, have myasthenia gravis or generalized disease, or neuromyelitis optica."

"The clinical trial mentioned is not currently looking for patients, as per the information available on clinicaltrials.gov. This particular trial was originally posted on December 20th 2016 and was edited most recently on July 14th 2022. There are 58 other trials which are actively recruiting patients."

"Ravulizumab was first studied in 2016 and, since then, 47 trials have completed. Currently, 25 clinical trials are recruiting patients with a notable number of these taking place in Los Angeles and Texas."